MENA emerging as trial destination says ClinTec CEO

Improving healthcare infrastructure across the region and a large treatment-naïve patient population makes the Middle East and North Africa (MENA) an increasingly attractive destination for drug trials says ClinTec CEO Rabinder Buttar.

Dr Buttar, who spoke with Outsoucing-pharma a few days after ClinTec reported a 45 per cent hike in 2009 sales, said that while the MENA trials sector is small on a global scale, the region has all the right elements for considerable growth.

She cited the growing number of new high-tech hospitals, the highly educated medical workforce and the increased presence of global regulators among MENA’s attractive features for trial sponsors.